^{2nd Middle East Pharmacy and Pharmaceutical Conference}

Nanotechnology is a frequently used approach to problem solving in disease treatment and it can be considered as a collection of tools and ideas that can be applied in the pharmaceutical technology. Chronic pain (CP) is generally known as any type of pain that lasts longer than 12 weeks. Drugs used to treat CP include analgesics such as opioids and nonsteroidal anti-inflammatory drug. Because of the low bioavailability of most drugs and/or the short half-life, the drugs in conventional treatment are not sufficient to treat CP. The development of new more effective therapeutic treatments for CP relief is essential for enhancing the patient quality of life and safety and avoiding or limiting risks of abuse, addiction or serious injuries posed by some of the present CP therapies. With this aim, several advanced Nanocarrier systems (NCSs) have been developed to increase bioavailability, therapeutic efficacy and safety. NCSs can be used effectively as a drug delivery system (DDS) with unique physicochemical-biological properties. The use of NCSs in the treatment of CP is one of the most popular research topics. For example, nanotechnology-based DDSs prepared with Eudragit&PLGA polymer of dexketoprofen trometamol that has a short-live, have entered the literature. Also, NCSs were prepared by using different polymers with flurbiprofen and ketoprofen lysine. When the results of the studies are examined, they are compared with the following results. Release rates of drugs with short half-lives were increased in vitro and in vivo. They concluded that side effects due to fluctuations in drug blood levels and toxicity, effective treatment and good patient compliance and the need for multiple dose regimens were eliminated, especially in oral administration. Nanotechnological DDSs capable of long-term drug release are new, important and promising systems for the treatment of CP with short half-life and low bioavailability drugs.